FATE THERAPEUTICS INC
FATE THERAPEUTICS INC (FATE): 72 pipeline candidates · 12 upcoming catalysts · ~17 mo cash runway · 42 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
16.5 months
3% dilution
Lead: Phase 3
72 candidates
12 upcoming, next in ~3d
0 buys · 4 sells (180d)
A transparent, data-derived signal for FATE THERAPEUTICS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$228.5M
Cash
$39.6M
Quarterly Burn
$30.8M
Runway
16.5 mo
Revenue
$1.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (72 candidates)
| Drug | Phase |
|---|---|
| 18F-NOTA-ABY-030 | Phase 1 |
| Adagrasib | Phase 2 |
| Amivantamab and Recombinant Human Hyaluronidase | Phase 2 |
| Anitocabtagene Autoleucel | Phase 3 |
| Bendamustine | Phase 2 |
| Bendamustine Hydrochloride | Phase 2 |
| BET Bromodomain Inhibitor ZEN-3694 | Phase 1 |
| BI 770371 | Phase 1 |
| Bleomycin | Phase 2 |
| Bortezomib | Phase 2 |
Showing 10 of 72 candidates. Sign up for full pipeline.
Upcoming Catalysts (12)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
154
Total value held
$73.3M
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 10,068,614 | $12.1M |
| vanguard capital management llc | 8,384,126 | $10.1M |
| vanguard portfolio management llc | 4,134,585 | $5.0M |
| two sigma investments, lp | 3,466,786 | $4.2M |
| johnson & johnson | 3,379,064 | $4.1M |
| aqr capital management llc | 3,001,521 | $3.6M |
| renaissance technologies llc | 2,974,683 | $3.6M |
| geode capital management, llc | 2,590,429 | $3.1M |
| state street corp | 2,263,173 | $2.7M |
| ubs group ag | 1,821,715 | $2.2M |
Showing top 10 of 154 institutional holders of FATE THERAPEUTICS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in FATE THERAPEUTICS INC's pipeline?
FATE THERAPEUTICS INC (FATE) has 72 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is FATE THERAPEUTICS INC's lead drug candidate?
FATE THERAPEUTICS INC's most advanced tracked candidate is 18F-NOTA-ABY-030 (Phase 1) for SCC - Squamous Cell Carcinoma.
What is FATE THERAPEUTICS INC's next catalyst?
FATE THERAPEUTICS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An International, Multicenter, Open-label, Randomized, Comparative Study of the Efficacy and Safety " — expected June 21, 2026.
What is FATE THERAPEUTICS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, FATE THERAPEUTICS INC has approximately 16.5 months of cash runway.
What is FATE THERAPEUTICS INC's market capitalization?
FATE THERAPEUTICS INC's market capitalization is approximately $228.5M.
Get the full picture on FATE THERAPEUTICS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.